Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

BA-BE Studies: SOP for Managing Medical Emergencies at Clinical Site – V 2.0

Posted on By

BA-BE Studies: SOP for Managing Medical Emergencies at Clinical Site – V 2.0

Standard Operating Procedure for Managing Medical Emergencies at Clinical Sites during BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/150/2025
Supersedes SOP/BA-BE/150/2022
Page No. Page 1 of 11
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define a structured protocol for identifying, managing, and documenting medical emergencies during the conduct of BA/BE studies at the clinical site to ensure subject safety, rapid intervention, and regulatory compliance.

2. Scope

This SOP applies to all volunteers enrolled in BA/BE studies being conducted at the clinical facility, and involves all medical, clinical, paramedical, and support personnel

present during study conduct.

3. Responsibilities

  • Principal Investigator (PI): Responsible for medical decision-making and authorization of hospital referral.
  • Medical Officer (MO): Provides immediate medical care and stabilizes the subject on site.
  • Clinical Research Coordinator (CRC): Assists in communication, documentation, and notifying sponsor and Ethics Committee.
  • Site Nurse: Provides first aid and supports the medical team during emergency management.
  • Security & Admin Team: Assists with ambulance coordination and evacuation procedures.
See also  BA-BE Studies: SOP for Reproducibility Assessment Across Runs - V 2.0

4. Accountability

The Medical Director and Head of Clinical Operations are accountable for ensuring readiness and compliance with emergency management procedures at all times.

5. Procedure

5.1 Emergency Preparedness

  1. Ensure availability of:
    • Emergency Medical Resuscitation Kit (Annexure-1)
    • Oxygen cylinders and pulse oximeter
    • Fully equipped ambulance with stretcher and paramedic staff
  2. Daily checks of emergency equipment must be recorded in Annexure-2: Emergency Equipment Checklist.
  3. Conduct mock drills every 6 months and document in Annexure-3: Emergency Drill Log.

5.2 Identification of Emergency

  1. Any of the following constitutes a medical emergency:
    • Syncope, seizure, respiratory distress
    • Anaphylaxis, cardiac arrest
    • Severe allergic reaction, uncontrolled bleeding
    • Unexpected loss of consciousness or unresponsiveness
  2. The nearest staff must immediately alert the MO and PI using emergency intercom or direct call.

5.3 Immediate Response and Stabilization

  1. The MO assesses the subject’s Airway, Breathing, and Circulation (ABC protocol).
  2. Initiate emergency care:
    • Administer oxygen
    • Perform CPR if necessary
    • Use Epinephrine in anaphylactic shock (0.3–0.5 mg IM)
    • IV fluids for hypotension
  3. Document vital signs every 2 minutes during intervention.

5.4 Transfer to Hospital

  1. Prepare Annexure-4: Medical Transfer Note with subject details, vitals, treatment given.
  2. Transport subject to designated hospital in coordination with ambulance team.
  3. A trained medical representative should accompany the subject with all relevant records.
See also  BA-BE Studies: SOP for Clinical Trial Insurance for BA/BE Studies - V 2.0

5.5 Communication and Notification

  1. Notify:
    • Sponsor – within 2 hours (Annexure-5: Emergency Communication Log)
    • Ethics Committee – within 24 hours using standard SAE format
  2. CRC to initiate an SAE form and compile a complete dossier (medical records, PI assessment, hospital notes).

5.6 Post-Emergency Review and CAPA

  1. Conduct Root Cause Analysis (RCA) and CAPA for all medical emergencies within 72 hours (Annexure-6: Emergency Review Form).
  2. Review must include:
    • Event cause and response timeline
    • Lessons learned and preventive recommendations

5.7 Training and Records

  1. All medical and clinical staff must be trained in BLS/ACLS annually.
  2. Maintain training attendance in Annexure-7: Medical Emergency Training Log.

6. Abbreviations

  • MO: Medical Officer
  • PI: Principal Investigator
  • CRC: Clinical Research Coordinator
  • EC: Ethics Committee
  • SAE: Serious Adverse Event
  • CAPA: Corrective and Preventive Action

7. Documents

  1. Emergency Resuscitation Kit Checklist – Annexure-1
  2. Emergency Equipment Checklist – Annexure-2
  3. Emergency Drill Log – Annexure-3
  4. Medical Transfer Note – Annexure-4
  5. Emergency Communication Log – Annexure-5
  6. Emergency Review Form – Annexure-6
  7. Medical Emergency Training Log – Annexure-7

8. References

  • ICH E6(R2) – Good Clinical Practice
  • Schedule Y – Drugs and Cosmetics Rules, India
  • Indian Resuscitation Council Guidelines

9. SOP Version

Version: 2.0

See also  BA-BE Studies: SOP for Project Risk Identification and Mitigation - V 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Emergency Resuscitation Kit Checklist

Item Quantity Status Checked By
Epinephrine 1mg/mL 5 vials Available Sunita Reddy
Oxygen Mask with Tubing 2 Available Sunita Reddy

Annexure-2: Emergency Equipment Checklist

Date Equipment Status Remarks Checked By
16/04/2025 Defibrillator Functional Battery charged Vinay Pawar

Annexure-3: Emergency Drill Log

Date Scenario Outcome Trainer
01/03/2025 Syncope during sampling Handled as per SOP Dr. Ajay Verma

Annexure-4: Medical Transfer Note

Subject ID VOL1201
Vitals BP: 90/60 mmHg, HR: 110 bpm
Treatment Given IV fluids, O2 support
Referred To Sparsh Hospital, Mumbai

Annexure-5: Emergency Communication Log

Date Notified To Mode Acknowledged By
17/04/2025 Sponsor Medical Monitor Email Dr. Neha Iyer

Annexure-6: Emergency Review Form

Date 18/04/2025
Event Summary Severe hypotension during post-dose monitoring
Root Cause Delayed hydration pre-dose
CAPA Ensure hydration at least 2 hours pre-dose

Annexure-7: Medical Emergency Training Log

Name Designation Training Date Trainer
Rajesh Kumar MO 10/02/2025 Dr. Priya Menon

Revision History:

Revision Date Revision No. Details Reason Approved By
01/01/2022 1.0 Initial release New SOP QA Head
17/04/2025 2.0 Annexures updated, expanded emergency procedures Inspection readiness QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: API Manufacturing: SOP for Investigation of Out-of-Trend (OOT) Results – V 2.0
Next Post: Gel Manufacturing: SOP for Conducting In-Process Testing During Gel Production – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2026 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version